Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141648
Status:
COMPLETED
Last Update Posted:
2009-10-01
First Post:
2005-08-30
Brief Title:
Chemotherapy and Radiotherapy for Osteolymphoma
Sponsor:
Trans Tasman Radiation Oncology Group
Organization:
Trans Tasman Radiation Oncology Group
Study Overview
Official Title:
A Prospective Non-randomised Trial of Chemotherapy and Radiotherapy for Osteolymphoma
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is intended to determine the results obtained when standard treatment for Non Hodgkins lymphoma is applied to the disease in a rare subtype which arises in bone Patients in the study undergo a detailed assessment then treatment with chemotherapy and radiotherapy followed by close monitoring
Detailed Description:
Patients with non-Hodgkins lymphoma arising primarily in bone have been studied using a number of different names making literature searching difficult The term Osteolymphoma has been proposed to make searching easier in the future Patients in this study undergoing staging which includes isotope bone scanning and PET scanning where available Eligible patients then undergo treatment with three cycles of CHOP chemotherapy at conventional doses and shrinking field radiotherapy to a total of 45 Gy Monoclonal antibodies are not included as good results have been obtained without using them After treatment the patients are regularly monitored The trial is presented twice per year at the meetings of TROG ALLG and AROLG
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ALLG LY-02 | None | None | None |